Title : A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.

Pub. Date : 2013 Sep

PMID : 23822584






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 KEY RESULTS: Dopamine, quipazine and VUF10166 were partial agonists at wild type 5-HT3A and 5-HT3AB receptors, with quipazine and VUF10166 causing a long-lived (>20 min) inhibition of subsequent agonist responses. Quipazine 5-hydroxytryptamine receptor 3A Homo sapiens
2 A T6"S substitution in the 5-HT3A subunit decreased EC50 and increased Rmax of dopamine and quipazine at both homomeric and heteromeric receptors. Quipazine 5-hydroxytryptamine receptor 3A Homo sapiens
3 CONCLUSIONS AND IMPLICATIONS: These results indicate that a mutation in the pore lining domain in both 5-HT3A and 5-HT3AB receptors alters the relative efficacy of a series of agonists, changing some (e.g. quipazine) from apparent antagonists to potent and efficacious agonists. Quipazine 5-hydroxytryptamine receptor 3A Homo sapiens